In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
2021 · Nature · 713 citations
https://doi.org/10.1038/s41586-021-03534-y
A
Alexandra C. Chadwick
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
38
Papers
2.1K
Citations
16
h-index
17
i10-index
Alexandra C. Chadwick is an academic researcher from Verve Therapeutics (United States). The author has contributed to research in topics: CRISPR and Genetic Engineering & Cholesterol and Lipid Metabolism & Cancer, Lipids, and Metabolism. The author has an h-index of 16, co-authored 33 publications.
ORCID: 0000-0002-4604-9227Papers by this author
worksTreatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing
2017 · Current Atherosclerosis Reports · 20 citations
https://doi.org/10.1007/s11883-017-0668-8
† VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies
2025 · Journal of clinical lipidology · 5 citations
https://doi.org/10.1016/j.jacl.2025.04.095
Nonclinical data demonstrate potent and precise inactivation of liver PCSK9 in vivo with the clinical stage GalNAc base editing medicine, VERVE-102
2025 · Atherosclerosis · 0 citations
https://doi.org/10.1016/j.atherosclerosis.2025.120333
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat